Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.

Abstract

11063 Background: Patient-reported outcomes (PROs) are essential for monitoring patient status and improving outcomes. ReX by Dosentrx physically administers oral medications and collects PROs at the time of dosing, allowing healthcare teams to track patient adherence, medication tolerance, and side effects. ReX aims to identify early toxicities between clinic visits, reduce acute care utilization, and improve adherence and overall outcomes. This study evaluates the impact of ReX on treatment adjustments and discontinuations in individuals taking either ribociclib or acalabrutinib. Methods: The study focused on a cohort of individuals prescribed either ribociclib or acalabrutinib. Patients using ReX were tracked for at least 6 months. The primary objective was to evaluate discontinuation rates at 3, 6, and 12 months. Secondary objectives included evaluating dose reductions and reasons for discontinuation. Outcomes from individuals using the ReX device were compared to a historical control group drawn from the same clinics prior to ReX implementation. Results: In the ribociclib group, 69 patients were in the historical control cohort and 63 in the ReX cohort, with median ages of 56 and 53, respectively. For acalabrutinib, the historical control had 94 patients and the ReX cohort 81, both with a median age of 70. Table 1 presents the discontinuation at 3, 6, and 12 months, along with the clinical reasons for discontinuation. Dose reductions were lower in the ReX group, with 11% for ribociclib at 10 months and 1% for acalabrutinib at 15 months, compared to 29% and 6% in the control group. Conclusions: ReX demonstrated a lower percentage of medication discontinuation at 3, 6, and 12 months for patients taking ribociclib or acalabrutinib, with fewer adverse event-related discontinuations and dose reductions compared to a historical control group. Additional studies investigating the impact of this novel medication delivery device on longer term medication adherence and clinical outcomes is currently underway. Discontinuation at 3, 6, and 12 months and reason for discontinuation. Discontinuation 3-months 6-months 12-months Control ReX Control ReX Control ReX Ribociclib 17.8% 6% 24.9% 11% 31.8% 11% Acalabrutinib 10.6% 2.5% 15% 8.6% 24.5% 13.5% Clinical Discontinuation Reason Disease Progression Adverse Events Medication Change Control ReX Control ReX Control ReX Ribociclib 55% 0% 27% 0% 18% 100% Acalabrutinib 55% 50% 27% 25% 18% 25%